Related Experiment Video
Updated: May 8, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
Oral agents for the management of gestational diabetes
Erica K Berggren1, Kim A Boggess
1*Department of Obstetrics and Gynecology, Thomas Jefferson University, Philadelphia, Pennsylvania †Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, North Carolina.
Abstract:
In gestational diabetes (GDM), achieving euglycemia through treatment decreases the risk of adverse outcomes associated with hyperglycemia. Treatment starts with diet and nutritional counseling; however, up to 50% of women will require pharmacologic therapy to meet glucose goals. Although insulin remains the only Federal Drug Administration-approved agent to treat GDM, oral hypoglycemic agents are an attractive and increasingly common alternative. Research suggests that glyburide and metformin can each effectively manage hyperglycemia in pregnancy. This review highlights research on efficacy, safety, and advantages versus disadvantages of each. We offer management and counseling strategies for clinicians caring for patients with GDM.
Related Concept Videos
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Oral Hypoglycemic Agents: Glinides
Diabetes Mellitus: Type 2 and Gestational
Dipeptidyl Peptidase 4 Inhibitors
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
